Boothbay Fund Management LLC Makes New $249,000 Investment in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Boothbay Fund Management LLC purchased a new stake in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 146,750 shares of the company's stock, valued at approximately $249,000. Boothbay Fund Management LLC owned approximately 0.36% of Vigil Neuroscience as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Blair William & Co. IL acquired a new stake in Vigil Neuroscience during the fourth quarter valued at $551,000. Renaissance Technologies LLC grew its stake in shares of Vigil Neuroscience by 698.5% in the 4th quarter. Renaissance Technologies LLC now owns 367,300 shares of the company's stock valued at $624,000 after buying an additional 321,300 shares in the last quarter. abrdn plc increased its holdings in Vigil Neuroscience by 124.9% in the fourth quarter. abrdn plc now owns 528,472 shares of the company's stock worth $898,000 after buying an additional 293,461 shares during the last quarter. Marshall Wace LLP increased its holdings in Vigil Neuroscience by 85.3% in the fourth quarter. Marshall Wace LLP now owns 266,895 shares of the company's stock worth $454,000 after buying an additional 122,853 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Vigil Neuroscience by 41.9% during the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company's stock valued at $769,000 after acquiring an additional 66,712 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. William Blair upgraded shares of Vigil Neuroscience to a "strong-buy" rating in a research note on Thursday, April 24th. Guggenheim restated a "buy" rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Wedbush decreased their price target on Vigil Neuroscience from $24.00 to $13.00 and set an "outperform" rating for the company in a research note on Friday, March 14th. Finally, HC Wainwright lowered their price objective on Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating on the stock in a report on Friday, March 14th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $16.25.

Vigil Neuroscience Price Performance

Shares of VIGL opened at $2.75 on Friday. The company has a market capitalization of $135.09 million, a PE ratio of -1.33 and a beta of 1.94. Vigil Neuroscience, Inc. has a one year low of $1.31 and a one year high of $6.06. The company's fifty day moving average price is $1.92 and its 200 day moving average price is $2.37.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.08). Analysts anticipate that Vigil Neuroscience, Inc. will post -2.07 earnings per share for the current year.

Vigil Neuroscience Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.